vs
瑞穗金融集团（FISI）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
瑞穗金融集团的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.8倍（$62.7M vs $35.5M），瑞穗金融集团净利率更高（33.5% vs -304.2%，领先337.7%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -2.0%）
瑞穗金融集团是一家总部位于日本东京千代田区大手町的银行控股公司，前身为2000年至2003年期间的瑞穗控股，由第一劝业银行、富士银行和日本兴业银行在2000至2002年间合并组建，是日本知名的大型金融集团。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
FISI vs RXRX — 直观对比
营收规模更大
FISI
是对方的1.8倍
$35.5M
净利率更高
FISI
高出337.7%
-304.2%
两年增速更快
RXRX
近两年复合增速
-2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $62.7M | $35.5M |
| 净利润 | $21.0M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 33.5% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | 24.3% | 39.6% |
| 每股收益（稀释后） | $1.04 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FISIRXRX
| Q1 26 | $62.7M | — | ||
| Q4 25 | $64.1M | $35.5M | ||
| Q3 25 | $63.8M | $5.2M | ||
| Q2 25 | $59.7M | $19.2M | ||
| Q1 25 | $57.2M | $14.7M | ||
| Q4 24 | $41.6M | $4.5M | ||
| Q3 24 | $50.1M | $26.1M | ||
| Q2 24 | $65.2M | $14.4M |
净利润FISIRXRX
| Q1 26 | $21.0M | — | ||
| Q4 25 | $20.0M | $-108.1M | ||
| Q3 25 | $20.5M | $-162.3M | ||
| Q2 25 | $17.5M | $-171.9M | ||
| Q1 25 | $16.9M | $-202.5M | ||
| Q4 24 | $-82.8M | $-178.9M | ||
| Q3 24 | $13.5M | $-95.8M | ||
| Q2 24 | $25.6M | $-97.5M |
毛利率FISIRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
营业利润率FISIRXRX
| Q1 26 | — | — | ||
| Q4 25 | 37.4% | -304.8% | ||
| Q3 25 | 39.5% | -3327.6% | ||
| Q2 25 | 36.0% | -916.8% | ||
| Q1 25 | 36.0% | -1297.9% | ||
| Q4 24 | -276.9% | -4042.4% | ||
| Q3 24 | 29.0% | -377.1% | ||
| Q2 24 | 46.2% | -697.4% |
净利率FISIRXRX
| Q1 26 | 33.5% | — | ||
| Q4 25 | 38.3% | -304.2% | ||
| Q3 25 | 32.1% | -3135.3% | ||
| Q2 25 | 29.3% | -894.2% | ||
| Q1 25 | 29.5% | -1373.3% | ||
| Q4 24 | -198.9% | -3935.5% | ||
| Q3 24 | 26.9% | -367.5% | ||
| Q2 24 | 39.3% | -676.6% |
每股收益（稀释后）FISIRXRX
| Q1 26 | $1.04 | — | ||
| Q4 25 | $0.96 | $-0.17 | ||
| Q3 25 | $0.99 | $-0.36 | ||
| Q2 25 | $0.85 | $-0.41 | ||
| Q1 25 | $0.81 | $-0.50 | ||
| Q4 24 | $-5.32 | $-0.56 | ||
| Q3 24 | $0.84 | $-0.34 | ||
| Q2 24 | $1.62 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $85.5M | $743.3M |
| 总债务越低越好 | $114.0M | $9.6M |
| 股东权益账面价值 | — | $1.1B |
| 总资产 | $6.3B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资FISIRXRX
| Q1 26 | $85.5M | — | ||
| Q4 25 | $108.8M | $743.3M | ||
| Q3 25 | $185.9M | $659.8M | ||
| Q2 25 | $93.0M | $525.1M | ||
| Q1 25 | $167.4M | $500.5M | ||
| Q4 24 | $87.3M | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M |
总债务FISIRXRX
| Q1 26 | $114.0M | — | ||
| Q4 25 | $193.7M | $9.6M | ||
| Q3 25 | $115.0M | $11.9M | ||
| Q2 25 | $115.0M | $14.2M | ||
| Q1 25 | $124.9M | $16.4M | ||
| Q4 24 | $124.8M | $19.0M | ||
| Q3 24 | $124.8M | $20.5M | ||
| Q2 24 | $124.7M | $22.9M |
股东权益FISIRXRX
| Q1 26 | — | — | ||
| Q4 25 | $628.9M | $1.1B | ||
| Q3 25 | $621.7M | $1.0B | ||
| Q2 25 | $601.7M | $919.1M | ||
| Q1 25 | $589.9M | $933.9M | ||
| Q4 24 | $569.0M | $1.0B | ||
| Q3 24 | $500.3M | $524.6M | ||
| Q2 24 | $467.7M | $584.4M |
总资产FISIRXRX
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $1.5B | ||
| Q3 25 | $6.3B | $1.4B | ||
| Q2 25 | $6.1B | $1.3B | ||
| Q1 25 | $6.3B | $1.3B | ||
| Q4 24 | $6.1B | $1.4B | ||
| Q3 24 | $6.2B | $726.5M | ||
| Q2 24 | $6.1B | $775.9M |
负债/权益比FISIRXRX
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | 0.01× | ||
| Q3 25 | 0.18× | 0.01× | ||
| Q2 25 | 0.19× | 0.02× | ||
| Q1 25 | 0.21× | 0.02× | ||
| Q4 24 | 0.22× | 0.02× | ||
| Q3 24 | 0.25× | 0.04× | ||
| Q2 24 | 0.27× | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流FISIRXRX
| Q1 26 | — | — | ||
| Q4 25 | $18.8M | $-46.1M | ||
| Q3 25 | $-6.9M | $-117.4M | ||
| Q2 25 | $-5.7M | $-76.4M | ||
| Q1 25 | $10.0M | $-132.0M | ||
| Q4 24 | $77.1M | $-115.4M | ||
| Q3 24 | $2.1M | $-59.2M | ||
| Q2 24 | $35.7M | $-82.2M |
自由现金流FISIRXRX
| Q1 26 | — | — | ||
| Q4 25 | $13.3M | $-47.3M | ||
| Q3 25 | $-7.9M | $-117.6M | ||
| Q2 25 | $-7.3M | $-79.6M | ||
| Q1 25 | $9.2M | $-133.8M | ||
| Q4 24 | $72.2M | $-116.7M | ||
| Q3 24 | $-299.0K | $-63.8M | ||
| Q2 24 | $34.7M | $-83.4M |
自由现金流率FISIRXRX
| Q1 26 | — | — | ||
| Q4 25 | 20.7% | -133.1% | ||
| Q3 25 | -12.4% | -2272.5% | ||
| Q2 25 | -12.3% | -413.9% | ||
| Q1 25 | 16.1% | -907.4% | ||
| Q4 24 | 173.3% | -2567.7% | ||
| Q3 24 | -0.6% | -244.6% | ||
| Q2 24 | 53.3% | -578.5% |
资本支出强度FISIRXRX
| Q1 26 | — | — | ||
| Q4 25 | 8.7% | 3.5% | ||
| Q3 25 | 1.6% | 4.7% | ||
| Q2 25 | 2.7% | 16.4% | ||
| Q1 25 | 1.4% | 12.4% | ||
| Q4 24 | 11.9% | 28.6% | ||
| Q3 24 | 4.9% | 17.5% | ||
| Q2 24 | 1.5% | 8.2% |
现金转化率FISIRXRX
| Q1 26 | — | — | ||
| Q4 25 | 0.94× | — | ||
| Q3 25 | -0.34× | — | ||
| Q2 25 | -0.33× | — | ||
| Q1 25 | 0.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 1.39× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FISI
| Net Interest Income | $52.0M | 83% |
| Noninterest Income | $10.7M | 17% |
RXRX
暂无分部数据
